Simcere Pharmaceutical Group Limited (Simcere Pharma) filed a Next Day Disclosure Return on 5 May 2026, confirming further progress under its on-market share repurchase programme.

On 5 May 2026 the company repurchased 1.38 million ordinary shares on the Hong Kong Stock Exchange at prices between HKD 11.60 and HKD 11.80, spending HKD 16.19 million. The shares, representing 0.053 % of Simcere Pharma’s issued share capital, are earmarked for cancellation.

Including this latest transaction, shares bought back but not yet cancelled in 2026 total 15.05 million, equivalent to 0.61 % of the share base as at the date of the repurchase mandate. The cumulative volume represents 6.08 % of the 247.47 million shares authorised for buyback under the mandate approved on 13 June 2025.

The company’s issued share capital stood unchanged at 2.60 billion shares as of 5 May 2026, pending cancellation of the repurchased stock. Under Hong Kong listing rules, Simcere Pharma is restricted from issuing new shares or selling treasury shares until 4 June 2026.